Basic HTML Version
93
SCIENTIFIC REPORT 2012
Title:
Phase Ib / II study of GDC-0068 or GDC-0980 plus abiraterone acetate versus
abiraterone acetate, in patients with castration-resistant prostate cancer who
have previously been treated with docetaxel-based chemotherapy.
District Attorney:
Genentech, Inc.
Principal Investigator:
Enrique Gallardo Diaz.
Title:
Concept test study, randomized, double-blind and placebo-controlled, of
maintenance therapy with tasquinimod in patients with metastatic prostate cancer
resistant to castration, which do not show progression after first line with chemotherapy
based on docetaxel.
District Attorney:
Ipsen Pharma SA
Principal Investigator:
Enrique Gallardo Diaz.
Title:
Sequential use of sorafenib and sunitinib in patients with metastatic renal cancer.
Spanish multicenter experience (NEXTEP).
District Attorney:
Bayer Hispania SL
Principal Investigator:
Enrique Gallardo Diaz.
Title:
Prospective observational study of treatment models and results of the
Real-world treatment in patients with advanced renal cell carcinoma or
metastatic patients receiving pazopanib.
District Attorney:
Glaxosmithkline SA
Principal Investigator:
Enrique Gallardo Diaz.
Title:
Phase IB / IIB study, randomized and multicenter, to evaluate the efficacy and tolerability of
the combination of Gefitinib and Olaparib (AZD2281) versus Gefitinib alone, in patients with
advanced non - small cell lung cancer with mutations in the receptor factor
epidermal growth (EGFR).
District Attorney:
Spanish Lung Cancer Group.
Principal Investigator:
Yolanda Garcia Garcia.
Title:
Phase II, open, single-arm, non-randomized, multicenter study to evaluate
the efficacy of oral TK1258 as second - line therapy in cancer patients
advanced and / or metastatic endometrium with mutated or wild-type FGFR2.
District Attorney:
Novartis Farmacéutica SA.
Principal Investigator:
Yolanda Garcia Garcia.